Novo Nordisk Valuation
| 0QIU Stock | 748.05 0.08 0.01% |
At this time, the firm appears to be undervalued. Novo Nordisk AS secures a last-minute Real Value of USD779.57 per share. The latest price of the firm is USD748.05. Our model forecasts the value of Novo Nordisk AS from analyzing the firm fundamentals such as Current Valuation of 2.96 T, return on equity of 0.82, and Profit Margin of 0.33 % as well as examining its technical indicators and probability of bankruptcy.
Enterprise Value 3 T | Price Sales 0.119 | Trailing PE 0.3896 |
Undervalued
Today
Please note that Novo Nordisk's price fluctuation is very steady at this time. Calculation of the real value of Novo Nordisk AS is based on 3 months time horizon. Increasing Novo Nordisk's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Novo stock is determined by what a typical buyer is willing to pay for full or partial control of Novo Nordisk AS. Since Novo Nordisk is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Novo Stock. However, Novo Nordisk's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 748.05 | Real 779.57 | Hype 746.43 |
The intrinsic value of Novo Nordisk's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Novo Nordisk's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Novo Nordisk AS helps investors to forecast how Novo stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Novo Nordisk more accurately as focusing exclusively on Novo Nordisk's fundamentals will not take into account other important factors: Novo Nordisk Total Value Analysis
Novo Nordisk AS is presently projected to have takeover price of 2.96 T with market capitalization of 19.9 B, debt of 12.96 B, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Novo Nordisk fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.96 T | 19.9 B | 12.96 B |
Novo Nordisk Investor Information
About 42.0% of the company shares are owned by institutions such as pension funds. The company recorded earning per share (EPS) of 21.5. Novo Nordisk AS had not issued any dividends in recent years. The entity had 5:1 split on the 2nd of January 2014. Based on the analysis of Novo Nordisk's profitability, liquidity, and operating efficiency, Novo Nordisk AS is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Total Cash From Operating Activities | 52.7 B | 63.2 B |
|
| |||||
| Operating Income | 57.5 B | 67.4 B |
|
|
Novo Nordisk Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Novo Nordisk has an asset utilization ratio of 72.39 percent. This implies that the Company is making USD0.72 for each dollar of assets. An increasing asset utilization means that Novo Nordisk AS is more efficient with each dollar of assets it utilizes for everyday operations.Novo Nordisk Ownership Allocation
Novo Nordisk AS maintains a total of 2.41 Billion outstanding shares. 30% of Novo Nordisk outstanding shares are owned by institutional investors. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Novo Nordisk Profitability Analysis
The company reported the revenue of 140.8 B. Net Income was 47.76 B with profit before overhead, payroll, taxes, and interest of 148.51 B.About Novo Nordisk Valuation
The stock valuation mechanism determines Novo Nordisk's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Novo Nordisk AS based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Novo Nordisk. We calculate exposure to Novo Nordisk's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Novo Nordisk's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 134.7 B | 113.1 B |
Novo Nordisk Quarterly Retained Earnings |
|
Additional Tools for Novo Stock Analysis
When running Novo Nordisk's price analysis, check to measure Novo Nordisk's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novo Nordisk is operating at the current time. Most of Novo Nordisk's value examination focuses on studying past and present price action to predict the probability of Novo Nordisk's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novo Nordisk's price. Additionally, you may evaluate how the addition of Novo Nordisk to your portfolios can decrease your overall portfolio volatility.